NeoGenomics, Inc. NEO was a giant mover final session, as the corporate noticed its shares rise gre
NeoGenomics, Inc. NEO was a giant mover final session, as the corporate noticed its shares rise greater than 5% on the day. The transfer got here on strong quantity too with way more shares altering fingers than in a traditional session. This continues the current uptrend for the corporate—because the inventory is now up 23.9% previously one-month timeframe.
The corporate has seen no adjustments in the case of estimate revision over the previous few weeks, whereas the Zacks Consensus Estimate for the present quarter has additionally remained unchanged. The current worth motion is encouraging although, so make sure that to maintain a detailed watch on this agency within the close to future.
NeoGenomics at the moment has a Zacks Rank #3 (Maintain) whereas its Earnings ESP is 0.00%.
NeoGenomics, Inc. Value
NeoGenomics, Inc. worth | NeoGenomics, Inc. Quote
A greater-ranked inventory within the Medical – Biomedical and Genetics business is QIAGEN N.V. QGEN, which at the moment carries a Zacks Rank #1 (Sturdy Purchase). You may see the entire record of at the moment’s Zacks #1 Rank shares right here.
The Hottest Tech Mega-Development of All
Final yr, it generated $24 billion in international revenues. By 2020, it is predicted to blast via the roof to $77.6 billion. Famed investor Mark Cuban says it should produce “the world’s first trillionaires,” however that ought to nonetheless go away loads of cash for normal traders who make the correct trades early.
See Zacks’ Three Finest Shares to Play This Development >>
Need the most recent suggestions from Zacks Funding Analysis? In the present day, you may obtain 7 Finest Shares for the Subsequent 30 Days. Click on to get this free report
QIAGEN N.V. (QGEN): Free Inventory Evaluation Report
NeoGenomics, Inc. (NEO): Free Inventory Evaluation Report
To learn this text on Zacks.com click on right here.
Zacks Funding Analysis
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.